AIM To evaluate the prognostic significance of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and prognostic nutritional index (PNI) and other clinicopathological factors in patients undergoing curative resection of colon cancer. METHODS 183 patients with histologically proven colorectal cancer who had undergone potentially curati...

The utility of CEA and CA19-9 as colorectal carcinoma (CRC) markers is limited and development of additional reliable markers is under investigation. We previously showed that galectin-1 is overexpressed in CRC tissues. If such a protein leaks into the peripheral circulation, it might constitute a tumor marker candidate. Here, we test the hypothesis that the levels of circulating galectins coul...

objective: to evaluate the effect of dialysis and kidney transplantation on serum levels of several tumor markers such as psa, afp, ca125, ca19- 9, ca15-3, cea and to compare with normal age matched controls. methods: between september of 2000 and july of 2001, the following tumor markers: psa, afp, ca125, ca19-9, ca15-3 and cea were measured by elisa method in 29 hemodialyzed patients (group a...

Background: Gastrointestinal cancer antigen CA19-9 is known as a valuable marker for the management of patients with pancreatic cancer. Methods: The analytical and clinical performance of the Access GI Monitor assay (Beckman Coulter) was evaluated on the UniCel DxI 800 Immunoassay System at five different European sites and compared with a reference method, defined as CA19-9 on the Elecsys Syst...

ancreatic ductal adenocarcinoma (PDAC) is a deadly Pmalignancy with an overall 5-year survival rate of 7%. By contrast, stage IA PDAC is associated with a 5-year survival rate of 40% after resection, underscoring the benefits of early diagnosis in conjunction with surgical intervention. Unfortunately, the vast majority of patients do not present with early PDAC, and approximately 80% of patient...

PURPOSE Each year in the United States, approximately 30,000 people die from pancreatic cancer. Fewer than 5% of patients survive >5 years after diagnosis, because most patients present with advanced disease. Early diagnosis may improve the prognosis of patients with pancreatic cancer. EXPERIMENTAL DESIGN In an attempt to improve on current approaches to the serological diagnosis of pancreati...